content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 18, 2004
                                                           ----------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                       000-14879              22-2322400
  ----------------------------      ------------------------   -------------------
  (State or Other Jurisdiction      (Commission File Number)   (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ             08540
  ------------------------------------------------------------    ----------------
           (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_| Written  communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_| Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  <PAGE>
  
  
  ITEM 8.01  OTHER EVENTS.
  
       On October 19, 2004,  Advanced  Magnetics,  Inc.  and  Cytogen  Corporation
  announced  that  Advanced  Magnetics  has  submitted a complete  response to the
  approvable letter received from the U.S. Food and Drug Administration  (FDA) for
  Combidex(R),   Advanced  Magnetics'  investigational  molecular  imaging  agent.
  Combidex  (ferumoxtran-10)  consists  of  iron  oxide  nanoparticles  for use in
  conjunction with magnetic resonance imaging (MRI) to aid in the  differentiation
  of cancerous from  non-cancerous  lymph nodes. The September 30, 2004 submission
  has been  accepted  and assigned a user fee goal date of March 30, 2005 by which
  date the FDA intends to review and act upon the submission.
  
       The full text of the October 19, 2004 press  release  issued in  connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
          Exhibit No.       Description
          -----------       -----------
              99.1          Press  Release of Advanced Magnetics and Cytogen dated
                            October 19, 2004
  
  
  
  <PAGE>
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                  CYTOGEN CORPORATION
  
  
  
                                                  By: /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:  October 19, 2004
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
          Exhibit No.       Description
          -----------       -----------
              99.1          Press  Release of Advanced Magnetics and Cytogen dated
                            October 19, 2004
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_101904.txt", "description": "FORM 8-K COMBIDEX", "secsgml_size_bytes": 4422}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "041084452"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 18, 2004
                                                           ----------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                       000-14879              22-2322400
  ----------------------------      ------------------------   -------------------
  (State or Other Jurisdiction      (Commission File Number)   (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ             08540
  ------------------------------------------------------------    ----------------
           (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_| Written  communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_| Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 8.01  OTHER EVENTS.
  
       On October 19, 2004,  Advanced  Magnetics,  Inc.  and  Cytogen  Corporation
  announced  that  Advanced  Magnetics  has  submitted a complete  response to the
  approvable letter received from the U.S. Food and Drug Administration  (FDA) for
  Combidex(R),   Advanced  Magnetics'  investigational  molecular  imaging  agent.
  Combidex  (ferumoxtran-10)  consists  of  iron  oxide  nanoparticles  for use in
  conjunction with magnetic resonance imaging (MRI) to aid in the  differentiation
  of cancerous from  non-cancerous  lymph nodes. The September 30, 2004 submission
  has been  accepted  and assigned a user fee goal date of March 30, 2005 by which
  date the FDA intends to review and act upon the submission.
  
       The full text of the October 19, 2004 press  release  issued in  connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
          Exhibit No.       Description
          -----------       -----------
              99.1          Press  Release of Advanced Magnetics and Cytogen dated
                            October 19, 2004
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                  CYTOGEN CORPORATION
  
                                                  By: /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:  October 19, 2004
  EXHIBIT INDEX
  
          Exhibit No.       Description
          -----------       -----------
              99.1          Press  Release of Advanced Magnetics and Cytogen dated
                            October 19, 2004